New emerging targets in cancer immunotherapy: the role of LAG3

Hannah Christina Puhr,1 Aysegül Ilhan-Mutlu2

ABSTRACT

The success of immunotherapy in many disease entities is limited to a specific subpopulation of patients. To overcome this problem, dual blockade treatments mainly against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death receptor (ligand) 1 (PD-(L)1) axis were developed. However, due to high toxicity rates and treatment resistance, alternative pathways and novel strategies were desperately needed. Lymphocyte-associated gene 3 (LAG3) represents an inhibitory receptor, which is mainly found on activated immune cells and involved in the exhaustion of T cells in malignant diseases. Its co-expression with other inhibitory receptors, particularly with PD-1, leads to an extensive research on the blockade of LAG3 and PD-1 in preclinical settings. Interestingly, several in-vivo approaches demonstrated a highly significant clinical benefit under dual blockade, whereas the efficacy was very low in case of single agent targeting. Moreover, human tumor tissues showed co-expression of LAG3 and PD-1 in infiltrated lymphocytes, which again generated a rationale for blocking these molecules in clinical settings. The ongoing clinical studies mainly use dual blockage of LAG3/PD-1, which demonstrated promising survival benefits and long duration of response rates. The following review focuses on the biological background and rationale of combining LAG3 with other agents and serves as an update on the state of clinical research on LAG3 targeting.

BIOLOGICAL BACKGROUND

Lymphocyte-associated gene 3 (LAG3) was identified in the 1990s as a novel transmembrane protein consisting of 489 amino acids with a structural homology to CD4, as both exhibit four extracellular domains.1 Furthermore, the LAG3 gene is located close to the CD4 gene on chromosome 12. Despite these similarities on chromosomal localisation and similar intron/exon organisation, only approximately 20% of the amino acid sequences of these two molecules were identical. Structural properties were also similar with same extracellular folding patterns, which resulted in binding of LAG3 to major histocompatibility complex (MHC) class II as a ligand, even with an up to 100 times higher affinity than CD4.2–4

LAG3 is mainly expressed in activated T and natural killer (NK) cells and was identified to as a marker for the activation of CD4+ and CD8+ T cells.5 Under pathological conditions, such as chronic inflammation or tumour environment, enhanced LAG3 expression on T cells was observed in combination with other inhibitory receptors such as programmed cell death receptor 1 (PD-1), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and TIM domain (TIM3), CD160, 2B4, which finally led to T cell dysfunction.6 Furthermore, LAG3 was mainly found on tumour infiltrating regulatory T cells (Tregs) in many types of cancer when compared with non-malignant peripheral cells.7

Apart from immune and cancer cells, high LAG3 mRNA expression was commonly found in the red pulp of the spleen, thymic medulla and at the base of the cerebellum.5 Modulation of LAG3 expression and its cleavage from the cell surface is an obligatory process for optimal T cell function. Via this cleavage, soluble LAG3 (sLAG3) is released to the circulation, where so far no clear biological function has been identified.8,9 Despite a lack of clinical evidence, detection of sLAG3 might serve as a prognostic biomarker in tuberculosis and as a diagnostic biomarker in type 1 diabetes.10,11 From a clinical perspective, sLAG3 might provide information on the activation status of LAG3 and could be used as a biomarker in clinical studies testing new immunotherapies. Recently, patients with metastatic hormone-receptor positive breast cancer receiving immunotherapy had longer disease free and overall survival rates, when sLAG3 was detectable in serum.12,13

The co-expression of LAG3 with other inhibitory molecules including PD-1, TIGIT, TIM3, 2B4, CD160 induces the exhaustion of immune cells, which results in diminished cytokine secretion.14,15 In line with these findings, the blockade of LAG3 on CD4 cells led to elevated production of interleukin (IL)-2, IL-4, interferon gamma and tumour necrosis factor alpha.16 Earlier studies demonstrated little effect of LAG3 blockade on the resolution of T cell exhaustion, whereas dual LAG3/PD-1 blockade provided very
significant results. Interestingly, both LAG3 and PD-1 deficient mice were usually capable to reduce large tumour volumes, whereas respective single knockouts showed only limited effects.17 In line with this finding, in colon adenocarcinoma and fibrosarcoma tumour models, anti-PD-1 monotherapy revealed only limited benefits with a tumour clearance of 40% and 20%, respectively, whereas this increased to 80% and 70% when dual blockade with LAG3/PD-1 compounds was used.17 18 Similar observations were reported in ovarian tumours,19 melanomas,20 lymphomas15 and multiple myelomas.21 As a hallmark of these in-vivo studies, increased survival and tumour clearance were mainly induced by repair of CD8+ T cell function and elevated cytokine production.

These highly significant in-vivo data demonstrate a clear synergy between LAG3 and PD-1 and accelerate the investigation of these inhibitory receptors on human samples and in further clinical trials as double blockade immunotherapies.

In humans, LAG3 was generally found to be co-expressed with PD-1, which together induced a T cell exhaustion state. Mainly, CD8+ positive tissue infiltrating lymphocytes isolated from patients with hepatocellular carcinoma, ovarian cancer and melanoma showed significant upregulation of LAG3 and high levels of PD-1.22-25 MHC class II molecules, as ligands of LAG3, are expressed in a variety of cells and tumours such as melanomas.26 LAG3 was frequently found to be ligated on MHC class II on melanoma cells, which lead to a clonal exhaustion of melanoma infiltrating T cells, thereby avoiding apoptosis.27 In colorectal cancer, LAG3 was found at higher extent in microsatellite instability high tumours, which are known to be susceptible to immunotherapy.28 Furthermore, LAG3 expression was found not only in tissue infiltrating lymphocytes but also in peripheral Tregs, tumour involved lymph nodes and within the tumour tissue itself, in melanoma and colon carcinoma.29 In patients with head and neck squamous cell carcinoma and non-small cell lung cancer, LAG3 was expressed on tumour infiltrating Tregs.30 31

### TARGETED AGENTS UNDER DEVELOPMENT

Targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and PD1/PD-L1 axis induced clinically relevant objective response rates and extended overall and progression free survival in patients with several different tumour types.32 33 However, the majority of patients does not respond or develops a treatment resistance after responding to an immunotherapy.34 35 Additionally, a significant increase of toxicity in patients receiving the dual treatment, particularly with CTLA4 inhibitors, became an important clinical problem.36 Hence, there exists a clinical need for the identification of more inhibitory receptors, which might contribute to and increase the activity of the up to now identified immunotherapy components. Besides from approaches, which test combination of immunotherapy with chemotherapy, radiation therapy or cancer vaccines, novel combinations focus on the dual immune checkpoint blockade. In this regard, novel inhibitory molecules including LAG3 and TIM3 are gaining more importance as new targets.15 37 The main goal of dual immunotherapy blockade should be the enhancement of the efficacy by extending progression free and overall survival without increasing the toxicity significantly.

The rationale of targeting LAG3 in addition to PD-1 and the strong preclinical data showing the efficacy of dual blockage of LAG3/PD-1 axis lead to the development of different drugs against the LAG3 molecule. First

---

**Table 1** Compounds developed to target the LAG3 molecule in different biological structures

| Name of the compound | Mechanism of action | Phase of clinical trial development | Company |
|----------------------|---------------------|-------------------------------------|---------|
| IMP321               | APC activator       | II                                  | Prima BioMed/Immutep |
| Relatlimab (BMS986016) | Fully human IgG4 mAb | III                                | Bristol-Myers Squibb |
| LAG525               | Fully human IgG4 mAb | II                                  | Novartis |
| MK-4280              | Fully human IgG4 mAb | I                                   | Merck |
| Sym-022              | Fully human Fc-inert mAb | I                                 | Symphogen |
| TSR-033              | Fully human IgG4 mAb | I                                   | Tesaro |
| REGN3767             | Fully human mAb     | I                                   | Regeneron Pharma/Sanofi |
| MGD013               | DART protein binding both LAG3 and PD1 | I                                 | MacroGenics |
| FS118                | Bispecific antibody binding both LAG3 and PD-L1 | I                                 | F-Star Delta |
| INCAGN02385          | Fc engineered IgG1k antibody | I                               | Incyte Biosciences |
| EOC202               | Human LAG-3 fusion protein | I                              | EddingPharm Oncology |

Only compounds, which entered clinical testing, are demonstrated in the table.

APC, antigen presenting cells; DART, dual affinity re-targeting; Ig, immunoglobulin; LAG3, lymphocyte-associated gene 3; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; mAb, monoclonal antibody.
Table 2  Current ongoing clinical trials investigating anti-LAG3 drugs in various solid tumours and haematological malignancies as of December 2018

| ClinicalTrials.gov identifier (or other database) | Tumour type | Setting (early or advanced disease, first, second or more lines if mts) | Phase | Treatment arms | Target accrual |
|--------------------------------------------------|-------------|---------------------------------------------------------------------|-------|---------------|----------------|
| NCT03252938                                     | Advanced solid tumours | Second line | I | IMP321 (injection directly into the tumour) | 38 |
| NCT03625323                                     | Advanced NSCLC Advanced HNSCC | First line or immunotherapy refractory Second line | II | IMP321+pembrolizumab | 120 |
| NCT02614833                                     | Met breast cancer, HR positive | First line | II | IMP321 | 241 |
| NCT02658981                                     | Glioblastoma | Second line | I | Relatlimab±nivolumab | 260 |
| NCT02061761                                     | B-Cell malignancies | Relapsed or refractory | I/IIa | Relatlimab±nivolumab | 132 |
| NCT01968109                                     | Advanced solid tumours | Second line (melanoma and NSCLC cohorts first line) I/IIa | Relatlimab±nivolumab | 1000 |
| NCT03610711                                     | Advanced gastro-oesophageal tumours | Second line | I | Relatlimab+nivolumab+RTX | 15 |
| NCT03044613                                     | Oesophagus and GEJ, stage II/III | First line | Relatlimab+nivolumab+RTX | 32 |
| NCT02966548                                     | Advanced solid tumours | Second line | I | Relatlimab±nivolumab | 45 |
| NCT03662659                                     | Advanced gastric or GEJ | First line | II | Relatlimab+nivolumab | 250 |
| NCT03459222                                     | Advanced solid tumours | First line | I/II | Relatlimab+nivolumab+ IDO inhibitor or relatlimab+nivolumab+ipilimumab | 230 |
| NCT03607890                                     | MSI-H solid tumours | Refractory to previous PD-(L)1 Treatment | II | Relatlimab+nivolumab | 21 |
| NCT02519322                                     | Resectable stage IIIB/IV Melanomas | First line, peri-Operative | II | Relatlimab+nivolumab | 53 |
| NCT02060188                                     | MSI-H and non MSI advanced colorectal cancer | First and further line | II | Relatlimab+Nivolumab | 340 |
| NCT03470922                                     | Advanced melanoma | First line | II/III | Relatlimab | 700 |
| NCT03642067                                     | MSS stable advanced colorectal carcinomas | Second and further line | II | Relatlimab+nivolumab | 64 |
| NCT02460224                                     | Advanced solid tumours | Second line I/II | LAG525±PDR001 | 515 |
| NCT03365791                                     | Advanced solid tumours and haematological malignancies | Second and further line | LAG525+PDR001 | 160 |
| NCT02720068                                     | Advanced solid tumours | Salvage setting | MK-4280+pembrolizumab | 408 |
| NCT03489369                                     | Advanced solid tumours or lymphomas | Second line or where no standard treatment available | I | Sym022 | 30 |
| NCT03250832                                     | Advanced solid tumours | Second line I | TSR-033±anti-PD-1 | 260 |
| NCT03005782                                     | Advanced solid tumours and lymphomas | Second line | REGN3767±REGN2810 | 546 |
| NCT03219268                                     | Advanced solid tumours and haematological malignancies | Second line | MGD013 | 243 |
| NCT03440437                                     | Advanced solid tumours and haematological malignancies | After PD-1/PD-L1 blockage | FS118 | 51 |

Continued
example was IMP321, which was designed to be a fusion recombinant protein having four extracellular domains like LAG3. This was followed by the development of monoclonal antibodies from various suppliers. Although these drugs are mainly used in clinical settings in combination with anti-PD-1 medication, some anti-LAG3 drugs were generated to be bispecific and target both LAG3 and PD-1, such as FS118 or dual affinity re-targeting protein MGD013.

These compounds, the mechanism of action and the producing company are summarised in table 1.

### CURRENT ONGOING CLINICAL TRIALS

The early phase I dose escalation trials of IMP321 as a monotherapy performed at patients with metastatic renal cell carcinoma tested subcutaneous administration of doses ranging between 0.05 mg and 30 mg. This was safe and well tolerated. The response rates were however modest and mainly observed in patients with higher doses. This early trial demonstrated the rationale of combining the anti-LAG3 regimen with chemotherapy or other immunotherapies in order to increase the response and survival rates. Based on these results, two further trials in advanced pancreatic cancer and metastatic breast cancer in combination with chemotherapy were designed. Within the first trial, IMP321 was combined with gemcitabine in patients with advanced pancreatic cancer. The efficacy and immunomodulation was insufficient that the authors recommended using higher doses of treatment in further trials. Within the second phase I trial, patients with metastatic breast cancer were treated with IMP321 in combination with paclitaxel in a first-line setting. Patients received different doses of IMP321 via subcutaneous injection every 2 weeks for 6 months. Toxicity was acceptable; there was a significant durable response with enhanced clinical outcome when compared with historical controls. The data of this trial lead to conduction of the placebo-controlled randomised phase II trial, where IMP321 was tested together with paclitaxel in patients with metastatic hormone receptor positive breast cancer. The preliminary efficacy data was demonstrated at American Society of Clinical Oncology (ASCO) congress in 2018. Here, a biweekly dose of 30 mg was recommended for further testing of the phase II trial, since this dose was shown to be the most effective with the least toxicity. IMP321 led to a steady and enhanced antigen-presenting cells (APC) and T cell activation. Within the same congress, the same dosage of IMP321 was demonstrated to be safe in combination with pembrolizumab in patients with melanoma who had a progressive disease after immunotherapy.

BMS-986016 (relatlimab) was the first anti-LAG3 mAb to be developed and is currently being evaluated in various clinical trials including solid tumours as well as haematological malignancies. The initial phase I/IIa trial of relatlimab sought to investigate the efficacy of the drug alone or in combination with nivolumab in patients with advanced diseases. The preliminary data of this trial investigating relatlimab and nivolumab in patients with melanoma who progressed after immunotherapy were demonstrated at ASCO congress in 2017. The efficacy was encouraging with an acceptable safety profile. At the time of the congress report, 31 patients had evaluable results with an ORR of 16% and DOR of 45%.

Further concepts of clinical trials testing other anti-LAG3 regimen were introduced at the latest large oncological congresses, and the data is expected to be published within the next few years. Table 2 summarises the ongoing clinical trials of various anti-LAG3 drugs in different settings. So far, relatlimab represents the only drug, which reached a phase III trial testing and several phase II approaches. Some other drugs including MK-4280, Sym022, TSR-033, REGN3767, MGD013, FS118, INCAGN02385 and EOC202 are in early phase I testing.

### CONCLUSIONS

Due to the success gained by the dual blockade of CTLA4 and PD-(L)1, new approaches for single immunotherapies, which might enhance their efficacy are established. In the last few years, LAG3 has gained widespread interest as an inhibitory receptor. Its synergistic biology with PD-1 provided a reasonable rationale to combine this molecule with anti-PD-1 agents. There are currently 11 molecules, which target LAG3 and are already being tested in clinical trials. The results of the early clinical trials demonstrate modest benefit of single anti-LAG3 treatment, which again supports potential combination approaches with other inhibitory receptors.

---

**Table 2 Continued**

| ClinicalTrials.gov identifier (or other database) | Tumour type | Setting (early or advanced disease, first, second or more lines if rmts) | Phase | Treatment arms | Target accrual |
|-------------------------------------------------|-------------|---------------------------------------------------------------|-------|---------------|---------------|
| NCT03538028                                     | Advanced solid tumours and lymphomas | Salvage setting | I | INCAGN02385 | 55 |
| NCT03600090                                      | Metastatic breast cancer | First line | I | EOC202+CHT | 18 |

CHT, chemotherapy; GEJ, gastro-oesophageal junction; HNSCC, squamous head and neck cancer; HR, hormone receptor; IDO, indoleamine (2,3)-dioxygenase; LAG3, lymphocyte-associated gene 3; MSI-H, microsatellite instability high; NSCLC, non-small cell lung cancer; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; RTX, radiation therapy.
There are still many unanswered questions regarding the LAG3 biology including its exact function and the existence of ligands other than the MHC class II. Until now, LAG3 has mainly been combined with the PD-(L)1 axis in clinical trials. If a combination with other inhibitory molecules is feasible or not still remains unclear. The clinical implications of LAG3 as a biomarker is also a less reported issue. Whether circulating soluble LAG3 or tissue expression of LAG3 could be used as biomarkers in the course of immunotherapy is now one of the questions, which hopefully will be answered in large clinical trials. Nevertheless, apart from the lack of knowledge on its function and its effector cells, preliminary data, which has been demonstrated so far by phase I trials and congress reports, shows promising and durable response rates with acceptable toxicity, making this molecule a focus of intensive research.

Contributors  
Consumer statement is accepted.  
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.  

Competing interests  
None declared.  

Patient consent for publication  
Not required.  

Provenance and peer review  
Not commissioned; internally peer reviewed.  

Open access  
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.  

REFERENCES  
1. Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990;171:1393–405.  
2. Huard B, Mastrandeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A 1997;94:5744–9.  
3. Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1996;26:2718–21.  
4. Weber S, Karjalainen K. Mouse CD4 binds MHC class II with extremely low affinity. Int Immunol 1993;5:695–8.  
5. Workman CJ, Rice DS, Dugger KJ, et al. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 2002;32:2255–63.  
6. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 2016;22:1856–64.  
7. Andrews LP, Marciscano AE, Drake CG, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017;278:80–96.  
8. Clayton KL, Douglas-Vail MB, Nur-ur Rahman AKM, et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol 2015;89:3722–36.  
9. Li N, Wang Y, Forbes K, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. Embo J 2007;26:494–504.  
10. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with decreased Th1 and increased Th2 activity in vivo. Eur J Immunol 2002;32:1605–13.  
11. Delmastro MM, Stychke AJ, Trucco MM, et al. Modulation of redox balance leaves murine diabetogenic Th1 T cells "LAG-3-ing" behind. Diabetes 2012;61:1760–8.  
12. Triebel F, Hacene K, Pichon M-F. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 2006;235:147–53.  
13. Li N, Workman CJ, Martin SM, et al. Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol 2004;173:6806–12.  
14. Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 2016;34:593–79.  
15. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016;44:889–1004.  
16. Huard B, Tournier M, Mercereau T, et al. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol 1994;24:3216–21.  
17. Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917–27.  
18. Waugh KA, Leach SM, Moore BL, et al. Molecular profile of tumour-specific CD8+ T cell hypofunction in a transplantable murine cancer model. J Immunol 2016;197:1477–88.  
19. Huang Y, Epp K, Legg S, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 2015;6:27359–77.  
20. Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumour-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013;190:4899–909.  
21. Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer 2015;3.  
22. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875–80.  
23. Baitsch L, Baumgartner P, Devèrèe E, et al. Exhaustion of tumour-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest 2011;121:2350–60.  
24. Taube JM, Young GD, McMiller TL, et al. Differential expression of Immune-Regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Cancer Res Clin Pract 2015;21:3969–76.  
25. Li F-J, Zhang Y, Jin G-X, et al. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. ImmunoLett 2013;150:116–22.  
26. Wolf DJ, Mattijssen V, Broecker EB, et al. MHC antigens in human melanomas. Semin Cancer Biol 1991;2:35–45.  
27. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011;186:5173–83.  
28. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43–51.  
29. Camisasci C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD8(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. Cancer Immunol Immunother 2011;60:6545–51.  
30. He J-B, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629–35.  
31. Wei T, Zhang J, Qin Y, et al. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Clin Oncol 2015;5:2190–201.  
32. Cousin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;343:1423–2.  
33. Gravitz L. Cancer immunotherapy. Nature 2013;504:51.  
34. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.  
35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.  
36. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:208–17.  
37. Turnis ME, Andrews LP, Vignali DAA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 2015;45:1892–905.  
38. Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of MP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009;15:6225–31.
39. Wang-Gillam A, Plambeck-Suess S, Goedegebure P, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. *Invest New Drugs* 2013;31:707–13.

40. Iouzalen N, Andreae S, Hannier S, et al. LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. *Eur J Immunol* 2001;31:2885–91.

41. Francois Duhoux P P, Dirix LY, Huizing MT. Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): final results from the run-in phase of a placebo-controlled randomized phase II. *J Clin Oncol* 2018;36.

42. Melissa A, Khattak MA, Roy AC, et al. Pushing the accelerator and releasing the brake: a phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. *J Clin Oncol* 2018;36.

43. Ascierto PA, Bhatia S, Bono P, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in PTS with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. *J Clin Oncol* 2017;35(15_suppl). (suppl; abstr 9520).